To explore the tolerability and pharmacokinetics of TQB2101 for injection in subjects with advanced malignant tumors.
The subjects voluntarily joined the study, signed the informed consent, and had good compliance;
18 years old ≤ age ≤75 years old (calculated on the date of signing the informed consent);
Eastern Cooperative Oncology Group (ECOG) score 0~1;
Expected survival greater than 12 weeks;
Had or was currently suffering from other malignant tumors within 3 years prior to the first medication.
There are multiple factors that affect intravenous injection, venous blood collection diseases, or have an impact on oral drugs.
The adverse reactions of previous treatment failed to recover to Common Terminology Criteria for Adverse Events Version 5 (CTCAEv5.0) score ≤1.
Patients who had major surgical treatment, significant traumatic injury, or potential major surgery during the expected study treatment period within 4 weeks prior to initial medication, or who had long-term unhealed wounds or fractures.